Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds

Calgary, Alberta–(Newsfile Corp. – October 27, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel“), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives such as DMT and psilocybin.

Marvel has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing. The compounds were administered for seven days, and preliminary evidence found multiple molecules with the same core structure capable of reducing depressive symptoms as measured in the widely accepted forced swim test. Early indications are extremely positive, with the swim test producing 2 positive indicators that exhibited strong potential for treatment.

Key features of the first class of molecules that Marvel has developed are:

  • fast acting
  • orally available
  • water soluble
  • no evidence of hallucinatory activity
  • significantly better (p<0.05) than fluoxetine (Prozac)

“Although early, this is an auspicious start for our new program that presents a compelling opportunity, as we further expand our product portfolio,” commented Dr. Mark Williams, President and Chief Science Officer. “We need to further characterize and expand upon the first set of hits we have identified, and we are also investigating molecules with very different structures to the known psychedelics to promote neuroplasticity as well. We are strong advocates for the use of psychedelic treatments to address mental health issues, yet it is critical that they are put through rigorous testing to ensure efficacy and safety for patients.”

“This program is in addition to our current development program of our caffeine inspired lead compound asset MB-204 being developed for neurological conditions such as depression and anxiety, Alzheimer’s disease (AD) and ADHD. MB-204 is in the manufacturing development phase and advancing well towards the clinic,” stated Rod Matheson, Chief Executive Officer. “We look forward to advancing this new program quickly owing to the potential breadth of neuroplastic agents to treat not only depression but PTSD, AD, Parkinson’s disease, autism, ALS, fetal alcohol exposure and schizophrenia for example.”

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones

Calgary, Alberta–(Newsfile Corp. – October 15, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the”Company“or”Marvel“), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient (“API”) of its lead drug MB-204, the Company has now entered an important milestone of engineering and subsequent current good manufacturing practices (“cGMP”) run of its multi-kilogram batches of MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. (“Ausun”).

The engineering run will provide the Company with a batch of its lead drug candidate MB-204 that can be used in good laboratory practice (“GLP”) toxicology studies, which are scheduled to begin in Q4 2021. Ausun will also be providing the Company with a cGMP batch of MB-204 that ensures identity, quality and purity in preparation of entering Phase I clinical studies in 2022 following the completion of the Company’s toxicology studies.

“To date we have shown in a number of pre-clinical studies the level of efficacy and safety MB-204 can deliver,” said Rod Matheson, Chief executive Officer of Marvel. “With the partnership we have in place with Ausun, we have now entered a key and very important stage in the development of MB-204 to drive this asset into clinical studies. These milestones are key in further advancing our discussions with potential commercial partners to ensure the best outcome for our shareholders.”

Marvel’s lead compound asset MB-204 (“MB-204”) is being developed for neurological conditions such as depression and anxiety, Alzheimer’s and ADHD. Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (“A2aR”). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

The upcoming Company milestones for its lead compound asset MB-204 include:

  • Completion of 2 kg of engineering run material in Q4 2021;
  • Initiation of IND-enabling toxicology studies in Q4 2021;
  • Completion of 2 kg of cGMP API in Q1 2022;
  • Completion of GLP toxicology expected Q2 2022; and
  • Initiation of Phase 1 with potential efficacy endpoints in Q3 2022.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081

Email: info@virtusadvisory.com 

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer’s Drug Discovery

Calgary, Alberta–(Newsfile Corp. – September 17, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the”Company“or”Marvel“), is pleased to announce that it has been accepted to present at the start-up company forum at the 22nd International Conference of Alzheimer’s Drug Discovery, a virtual conference on October 4 and 5th, 2021 hosted by the Alzheimer’s Drug Discovery Foundation.

The 2020 conference attracted close to 900 attendees from around the world. Attendees included: academic and industry scientists, business development and licensing professionals, venture capitalists and other investors.

“Our pre-clinical data to date has shown great promise in terms of efficacy and safety of our lead compound MB-204,” said Dr. Mark Williams, President and Chief Science Officer, who will be giving the presentation. “Establishing strategic R&D and commercialization partnership is key to our overall business strategy, and an opportunity to increase visibility among industry leaders as we actively move our lead compound through key developmental milestones is fundamental to our business.”

Marvel’s lead compound asset MB-204 is being developed for neurological conditions such as depression and anxiety, Alzheimer’s and ADHD. Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (“A2aR”). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations: 
Virtus Advisory Group
Tel: 416-644-5081

Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases

Calgary, Alberta–(Newsfile Corp. – August 5, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel“), is pleased to provide an update on its lead compound asset MB-204 (“MB-204”) being developed for neurological conditions such as depression and anxiety, Alzheimer’s and ADHD. Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (“A2aR”). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

The Company has observed the following key pre-clinical properties of its lead asset MB-204:

  • The compound is an antagonist of A2aR with a consistently similar in vitro IC50 as Istradefylline (75 vs 67 nM respectively);
  • The compound has a very favourable oral pharmacokinetic profile in mice with a higher bioavailability (56% vs 30.9%) and longer half life than Istradefylline (2.9 vs 2.2 hours), the latter property confirmed by in vivo brain receptor occupancy studies (p<0.01);
  • Demonstrated a clear dose dependent reduction in immobility time (p<0.0001) in a forced swim test model of depression at doses that did not trigger an increase in general locomotive activity;
  • In a head-to-head study with Istradefylline conducted in an elevated plus model of anxiety, MB-204 exhibited a superior anti-anxiety profile;
  • A slightly better toxicity profile (lower liver enzymes, ALT and AST) and lower creatinine levels than Istradefylline in a sub-chronic dosing experiment.

This data in totality suggests MB-204 could be dosed as a once-a-day oral agent, possessing an attractive profile for central nervous system (“CNS”) diseases involving A2aR.

“We based our molecule MB-204 off Istradefylline, the only US-FDA clinically approved A2aR antagonist, making logical changes to the original molecule to retain activity, but improve other qualities such as oral bioavailability” said Dr. Mark Williams, President and Chief Scientific Officer of Marvel. “The results we have received so far in our pre-clinical studies are highly encouraging and gives us a high degree of confidence in potential applications of MB-204 in helping a growing number of patients suffering from neurological diseases, such as depression and Alzheimer’s disease. In our studies we saw that not only did our compound bind to the right target in the brain, the A2aR receptor, but a high concentration of it was able to enter the brain upon oral consumption and its effect lasted longer than Istradefylline.”

“Our goal is to develop an asset that may have multiple applications,” said Rod Matheson, Chief Executive Officer of Marvel. “We like to describe MB-204 as a ‘pipeline in a product’ as it may have more than one central nervous system indication, and it may also have applications outside neurological diseases such as non-alcoholic steatohepatitis (“NASH”) and cancer. We believe by having more than one, unrelated disease MB-204 can go after, the Company de-risks the development of this asset.”

Marvel previously announced on July 21, 2021 that the Company had entered into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical Co., Ltd. (“Ausun”) for the supply of its lead asset MB-204 for GLP pre-clinical toxicology studies and clinical trials.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations: 
Virtus Advisory Group
Tel: 416-644-5081

Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Dr. Mark Williams, President and Chief Science Officer
Tel: 403-770-2469

Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES

2021-08-03 17:38 ET – News Release

 

Mr. J. Roderick (Rod) Matheson reports

MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES

Marvel Biosciences Corp. has retained Virtus Advisory Group Inc. to develop and implement a strategic corporate communications program to increase the company’s exposure among industry stakeholders and investors across Canada.

In connection with the engagement, Virtus has been awarded a consulting contract that includes a monthly fee of $7,000 and a grant of incentive stock options, which will vest in equal instalments over a 12-month period, to acquire 400,000 common shares of the company, exercisable at a price of 40 cents per share for a period of five years from date of grant. The 400,000 incentive stock options are subject to board of director approval, regulatory approval and policies as applicable by the TSX Venture Exchange, and may only vest and be exercised after disinterested shareholder approval of the company’s stock option plan at the next shareholders meeting held by the company.

About Virtus Advisory Group

Virtus is a Toronto-based consulting firm, providing select private and publicly listed companies with business consulting, capital markets strategy and investor relations services. The company provides expert counsel and access to an unmatched network of investors and capital markets professional across Canada and the United States. Virtus helps issuers establish the relationships and the investor confidence required to build long-term shareholder value.

About Marvel Biosciences Corp.

Marvel Biosciences, and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based biotechnology company that utilizes a drug redevelopment approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified that involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the company. The company believes the business model results in significantly less risk, cost and time to develop its assets compared with traditional biotechnology companies.

Marvel Biotechnology has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel Biotechnology is also exploring additional undisclosed targets to expand its asset pipeline.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.

MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204

2021-07-21 12:37 ET – News Release

Dr. Mark Williams reports

MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204

Marvel Biosciences Corp.’s wholly owned subsidiary Marvel Biotechnology Inc. has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology has entered into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical Co., Ltd. (Ausun) for the supply of its lead asset MB-204 for toxicology studies and clinical trials. MB-204 is the company’s lead compound with potential application to the neurological diseases of depression and anxiety, Alzheimer’s, ADHD (attention-deficit/hyperactivity disorder) and non-neurological diseases such as cancer and non-alcoholic steatohepatitis.

Ausun was chosen and the agreement entered into as a result of an extensive request for proposal (RFP) process and negotiations undertaken by Marvel Biotechnology for the pilot manufacturing of its lead compound, MB-204. The company believes that Ausun possesses the expertise in process development and custom manufacturing of active pharmaceutical ingredients, intermediates and formulated products, and will develop the chemical process and manufacture of Marvel’s MB-204 active pharmaceutical ingredient (API) formulation.

“This is a major science milestone event for the company as we work to achieve and develop our lead asset MB-204 for clinical testing and commercialization,” stated Dr. Mark Williams, president and chief science officer of Marvel. “This program has now commenced and follows after the completion of our reverse takeover and amalgamation transaction with our partners at Alphanco, and the recommencement of trading on the TSX-V last week as Marvel Biosciences Corp. We look forward to updating the market on our progress and the lead asset MB-204.”

About Marvel Biosciences Corp.

Marvel Biosciences, and its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company that utilizes a drug redevelopment approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target but typically only approved for a specific disease. Often, a new disease is identified which involves the same target; however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the company. The company believes the business model results in significantly less risk, cost and time to develop its assets compared with traditional biotechnology companies.

Marvel Biotechnology has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer’s, ADHD) and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.

ALPHANCO VENTURE CORP. CHANGES NAME TO MARVEL BIOSCIENCES CORP. AND COMPLETES ACQUISITION OF MARVEL BIOTECHNOLOGY INC.

Calgary, Alberta, July 8, 2021 – Alphanco Venture Corp. (TSX-V: AVC.P) (the“Company”or“AVC”), a capital pool company listed on the TSX Venture Exchange (the “TSXV”), is pleased to announce that it has closed its proposed “Qualifying Transaction”, as defined under TSXV policies, being the acquisition of all of the outstanding shares (the “Transaction”) of Marvel Biotechnology Inc. (“Marvel Biotech”) effective June 14, 2021. In connection with closing of the Qualifying Transaction, AVC has changed its name to Marvel Biosciences Corp.

The arm’s length acquisition of Marvel Biotech was structured as a three-cornered amalgamation, whereby AVC acquired all of the issued and outstanding shares of Marvel Biotech through an amalgamation between a wholly owned subsidiary of AVC and Marvel Biotech. The amalgamation resulted in the shareholders of Marvel Biotech receiving common shares of AVC (the “Common Shares”) as consideration under the amalgamation and Marvel Biotech becoming a wholly-owned subsidiary of the Company.  The Transaction is classified as a reverse take-over.

Final approval of the Transaction will occur upon the issuance of the Final Exchange Bulletin (the “Bulletin”) by the TSXV. Subject to final acceptance by the TSXV, the Common Shares of Marvel Biosciences Corp. are expected to commence trading on the TSXV under the symbol “MRVL on or about July 12, 2021, and the Company will be classified as a Tier 2 life sciences issuer pursuant to TSXV policies.

Shareholders of the Company are not required to take any action with respect to the name change and are not required to exchange any existing certificates bearing the Company’s old name. The Company’s transfer agent and registrar, Odyssey Trust Company, will send registered shareholders a new Direct Registration System statement representing the number of Common Shares held by such shareholders.

A copy of the Company’s press releases and TSXV Filing Statement, which contains comprehensive disclosure on the Transaction and the business of the Company and Marvel Biotech, has been filed on SEDAR under the Company’s profile at www.SEDAR.com .

Private Placement Financing Conditions to Final TSXV Acceptance

As part of the TSXV conditional approval of the Transaction and issuance of the Bulletin, the Company was required to complete a private placement financing (the “Financing’) of a minimum of 6,400,000 Common Shares of the Company at a price of $0.40 per share for proceeds of $2,560,000.  On June 10, 2021, the Company completed the Financing for gross proceeds of $2,616,000 through the issuance of 6,540,000 Common Shares at $0.40 per share. A cash finder’s fee of $144,000 was paid to eligible finders in connection with the Financing.

All securities issued in connection with the Financing are subject to a statutory hold period of four months plus a day, expiring October 11, 2021 in accordance with applicable securities legislation.

Proceeds from the Offering will be used for Company operations and in support of the cGMP synthesis and GLP toxicology studies of its lead asset, MB-204 with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. Proceeds will also be used for further research on MB-204 and additional potential pipeline products in development or to be identified as a result of internal research; and for general working capital purposes.

Additional information on the Company

In connection with the Transaction, Marvel Biosciences Corp. board of directors has been reconstituted and is now comprised of the following individuals: 

Joanne Yan

Neil A Johnson

Jeremy Fehr

J. Roderick (Rod) Matheson – Chief Executive Officer

Dr. Mark Williams – President and Chief Science Officer

In addition, the Company has appointed Preston J. Maddin as Chief Financial Officer and Jacqueline Groot as Corporate Secretary.

Capital Structure

Upon issuance of the Bulletin, including the Financing, the issued and outstanding share capital of the Company consists of 32,586,231 Common Shares, including 6,540,000 Common Shares issued pursuant to the Financing. The Company will also have 10,071,533 warrants outstanding at various dates of maturity up to April 30, 2023.

A total of 14,250,098 Common Shares will be subject to escrow agreements, including 2,700,000 Common Shares originally issued to the Company’s principals upon listing the Company as a “capital pool company” (the “CPC Escrow Shares“), and 11,400,098 Common Shares issued to principals in connection with the Transaction (the “Value Escrow Shares“). 25% of the CPC Escrow Shares will be released from escrow upon issuance of the Bulletin, with an additional 25% every six months thereafter. 10% of the Value Escrow Shares will be released upon issuance of the Bulletin and 15% every six months thereafter.

A total of 1,775,000 warrants are subject to a Tier 2 value escrow and will be released from escrow on the same terms as the Value Escrow Shares.

“We are pleased to announce the completion of this significant milestone for our Company and with our partners at Alphanco”, stated Rod Matheson, CEO of Marvel Biotech. “This financing will allow Marvel Biotech to develop its lead asset MB-204 for clinical testing. We look forward to updating the market on our progress and MB-204 with application to the neurological diseases of depression & anxiety, Alzheimer’s, ADHD and addiction, cancer, and the application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis.”

About Marvel Biotechnology Inc.

Marvel Biotechnology Inc., a wholly owned subsidiary of Marvel Biosciences Corp., is a Calgary-based biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but often only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the same drug may not have sufficient time left for it to be commercially viable to developed it for the new indication. Marvel Biotech utilizes a non-traditional biotechnology model in that it has identified assets or compounds that have come off patent protection, and unlike a traditional redevelopment biotechnology model, develops synthetic chemical derivatives to significantly enhance certain compounds that results in a new novel and patentable asset. The business model result is that there is significantly less risk, cost and time to develop our assets compared to traditional biotechnology companies with the objective of developing or partnering the assets for commercialization.

Marvel Biotechnology Inc. has currently developed several new patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. Marvel Biotech is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

For further information please contact:

J. Roderick (Rod) Matheson, CEO                            

Marvel Biosciences Corp.                                         

Email: info@MarvelBiotechnology.com                  

Phone: 403 770 2469

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Issuance of the Final TSXV Bulletin is subject to a number of conditions, including but not limited to TSXV acceptance and submission of conditional approval documents post-closing of the Transaction. 

Where applicable, the Transaction cannot close until the required TSXV approval is obtained.  There can be no assurance that the Transaction will be approved as proposed or at all.

Investors are cautioned that, except as disclosed in the TSXV Filing Statement (or other disclosure documents to be prepared by the Company) prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon.  Trading in the securities of an emerging junior company should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

All information contained in this news release with respect to AVC and Marvel Biotech was supplied by the parties, respectively, for inclusion herein, and each parties’ directors and officers have relied on each other for any information concerning such party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Proposed Transaction and the future plans and objectives of the Company and Marvel Biotech are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and Marvel Biotech include the failure to obtain approval from the TSXV for the Transaction and other risks detailed from time to time in the filings made by the Company and Marvel Biotech under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company and Marvel Biotech. As a result, the Company and Marvel Biotech cannot guarantee that the Transaction will be approved on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company and Marvel Biotech will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Alphanco receives conditional OK for Marvel acquisition

2021-03-18 16:43 ET – News Release

Ms. Joanne Yan reports

ALPHANCO VENTURE CORP. ANNOUNCES CONDITIONAL APPROVAL FOR ITS ACQUISITION OF MARVEL BIOTECHNOLOGY INC.

Alphanco Venture Corp. has received conditional approval from the TSX Venture Exchange for its acquisition of all of the outstanding shares of Marvel Biotechnology Inc. as its proposed qualifying transaction as defined under TSX-V policies.

A copy of the company’s TSX-V filing statement, which contains comprehensive disclosure on the proposed transaction and the business of the company and Marvel, has been filed on SEDAR under the company’s profile. Closing of the proposed transaction is expected to occur at the end of April, 2021.

Conditions to closing the proposed transaction

As part of the TSX-V conditional approval of the proposed transaction, the company is required to complete a private placement financing of a minimum of 6.4 million common shares of the company at a price of 40 cents per share for gross proceeds of $2.56-million. The company has previously disclosed that it intended to complete a financing for maximum proceeds of up to $4-million through the issuance of 10 million common shares at 40 cents per share.

About Marvel

Marvel is a Calgary-based biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but often only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the same drug may not have sufficient time left for it to be commercially viable to developed it for the new indication. Marvelutilizes a non-traditional biotechnology model in that it has identified assets or compounds that have come off patent protection, and unlike a traditional redevelopment biotechnology model, develops synthetic chemical derivatives to significantly enhance certain compounds that results in a new novel and patentable asset. The business model result is that there is significantly less risk, cost and time to develop the company’s assets compared with traditional biotechnology companies with the objective of developing or partnering the assets for commercialization.

Marvel has currently developed several new patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer’s, ADHD, and addiction), cancer and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

About AVC

Alphanco Venture is a capital pool company pursuant to the policies of the TSX Venture Exchange with a view to completing a qualifying transaction. Management of the company has been actively engaged in assessing possible projects with a view to completing an acquisition, and is working toward completing its proposed qualifying transaction.

Completion of the proposed transaction is subject to a number of conditions, including but not limited to, TSX-V acceptance and if applicable pursuant to TSX-V requirements, majority of the minority shareholder approval.

Where applicable, the proposed transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the proposed transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the TSX-V filing statement, any information released or received with respect to the proposed transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

All information contained in this news release with respect to Alphanco and Marvel was supplied by the parties, respectively, for inclusion herein, and each parties’ directors and officers have relied on each other for any information concerning such party.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.

Alphanco to acquire Calgary biotech company as QT

2020-11-03 10:57 ET – News Release

Mr. Roderick Matheson reports

ALPHANCO VENTURE CORP. TO ACQUIRE MARVEL BIOTECHNOLOGY INC. IN A REVERSE TAKEOVER TRANSACTION

Alphanco Venture Corp. has signed a merger agreement dated Oct. 28, 2020, pursuant to which the company will acquire all of the outstanding shares of Marvel Biotechnology Inc. The proposed transaction is intended to be a qualifying transaction for the company as defined under TSX Venture Exchange policies. A copy of the agreement is available under the company’s profile on SEDAR.

Marvel was incorporated pursuant to the Business Corporations Act (Alberta) on Aug. 1, 2018, and is a Calgary-based biotechnology company that utilizes a target repurposing approach to drug development in large markets that have few or no competitors. Marvel is focused on a non-traditional biotech model in that it identifies assets, compounds or new chemical entities that have come off patent protection for certain already approved disease indications. Unlike a traditional or repurposing biotech model, Marvel develops synthetic chemical derivatives to significantly enhance certain compounds that results in a new novel and patentable asset for a new disease indication. The result is that there is significantly less cost and time to develop Marvel’s assets compared with traditional biotech companies.

Marvel has currently developed several new patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer’s, attention-deficit/hyperactivity disorder and addiction), cancer and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

The controlling shareholder of Marvel is Renaissance Mercantile Corp., which is controlled by J. Roderick Matheson.

Summary of the proposed transaction

The proposed transaction will be completed by way of a merger between Marvel and a newly incorporated and wholly owned Alberta subsidiary of the company. Marvel will become a wholly owned subsidiary of the company on completion of the proposed transaction by way of the shareholders of Marvel exchanging their shares in Marvel at a ratio of 1 to 1 for shares of the company at a deemed price of 40 cents per company share. Other than the issuance of company shares, there is no other consideration payable by the company to acquire Marvel. Upon completion of the proposed transaction, the company will continue on with the business of Marvel and, accordingly, the resulting issuer intends to list as a Tier 2 life sciences issuer on the TSX-V.

In connection with the proposed transaction, the resulting issuer intends to appoint five directors to its board of directors, to continue its corporate status into Alberta, to appoint MNP LLP as its auditors and approve a new stock option plan. AVC has called a shareholder meeting to approve these matters to be effective on completion of the proposed transaction.

Prior to the closing of the proposed transaction, the company intends to change its name to Marvel Biotechnology Corp., or such other name as may be agreed upon the parties.

On completion of the proposed transaction and financings:

  1. The shareholders of Marvel will exchange their shares for shares of the resulting issuer at the deemed QT price and will hold up to approximately 15,610,098 common shares of the resulting issuer for a deemed total valuation of Marvel of approximately $6.25-million; and
  2. The shareholders of Marvel will exchange their 16,668,200 common share purchase warrants at varying exercise prices and varying terms at a ratio of 1 to 1 for common share purchase warrants issued by the resulting issuer at duplicate exercise prices and terms, not including the potential exercise of up to five million common share purchase warrants held by a founder of Marvel.

In the event the founder warrants are exercised, the shareholders of Marvel will hold approximately 20,610,098 common shares of the resulting issuer at the deemed QT price and 11,668,200 common share purchase warrants at varying exercise prices and varying terms.

No deposits, advances or loans have been made by the company to Marvel and none are contracted to be made pursuant to the agreement.

The company will be seeking a waiver of the sponsorship requirements of TSX-V Policy 2.2 Sponsorship and Sponsorship Requirements, but there is no assurance that such waiver will be granted.

Conditions to the proposed transaction

The completion of the proposed transaction remains subject to a number of terms and conditions customary for transactions of this nature, including regulatory and shareholder approval of the matters contemplated by the agreement and the satisfactory completion of due diligence on the company by Marvel.

As a condition of completion of the proposed transaction and subject to the minimum AVC participation, the resulting issuer will complete, concurrent with closing, a non-brokered private placement of a minimum five million shares and up to a maximum of 10 million resulting issuer shares at a price of 40 cents per resulting issuer share, for aggregate gross proceeds of a minimum $2-million and a maximum of $4-million. Finder’s fees may be payable on a portion of the concurrent financing to eligible finders.

Pursuant to the merger agreement and the execution of a subsequent definitive agreement, AVC has committed to AVC shareholders or purchasers sourced by AVC purchasing a minimum of $1-million worth of securities in connection with this transaction made up of the aggregate dollar amount taken down by such purchasers in (i) the Marvel private placement of up to $250,000, and (ii) the balance of a minimum $750,000 of the concurrent financing, as totals $1-million (or more) (referred to as the minimum AVC participation). It is expected that insiders of Marvel, their assigns or their friends, family, business associates or accredited investors shall subscribe for a minimum of $2-million in the concurrent financing.

In addition, pursuant to the terms of the merger agreement, 670,000 outstanding AVC stock options will be cancelled.

Financings

Marvel is also in the process of completing an additional private placement to finance further clinical studies and for general corporate purposes. Prior to Nov. 13, 2020, Marvel intends on completing, in one or more closings, a non-brokered unit private placement at 30 cents per unit of no less than $250,000 (of which $106,000 has been raised so far) and no more than $500,000, each unit consisting of a common share and a common share purchase warrant, with each warrant entitling the holder to purchase an additional common share at 50 cents per share for a period of 24 months. Marvel has granted AVC the option for AVC shareholders or purchasers sourced by AVC to purchase up to $250,000 of the Marvel private placement. No further issuances of securities by Marvel will occur prior to the closing of the proposed transaction.

Share capital and escrow

On completion of the proposed transaction and the concurrent financing, the company is anticipated to have approximately the following capitalization:

  • Up to a minimum 32,310,098 and maximum 37,310,098 resulting issuer shares.
  • Up to 12,068,200 resulting issuer share warrants to purchase resulting issuer shares inclusive of 400,000 broker warrants already issued and prior to the concurrent financing.

The resulting issuer intends to grant stock options pursuant to a new stock option plan. A finder’s fee in the amount of $5,000 plus applicable taxes will be paid on completion of the proposed transaction.

It is anticipated that current securityholders of the company are expected to hold approximately 20.7 per cent of the resulting issuer assuming the minimum concurrent financing or 18 per cent of the resulting issuer shares assuming the maximum amount of the concurrent financing, and approximately 15.1 per cent (minimum concurrent financing) or 13.6 per cent (maximum concurrent financing) on a fully diluted basis.

Securities issued to Marvel shareholders by AVC pursuant to the proposed transaction (other than those issued pursuant to the concurrent financing and or other than prescribed exceptions in TSX-V policies), held by principals of the resulting issuer, are subject to escrow, and all securities held by non-principals are subject to seed share resale restrictions. No new insiders of the resulting issuer (excluding those in their capacities as proposed directors and officers) are expected to be created under the proposed transaction.

The common shares of the company were halted, effective Oct. 28, 2020, and are not expected to recommence trading on the TSX-V prior to completion of the proposed transaction. The proposed transaction is anticipated to close on or before Feb. 1, 2021. The proposed transaction is not a non-arm’s-length qualifying transaction as such term is defined under TSX-V policies.

Proposed directors and officers of the resulting issuer

On completion of the proposed transaction, the directors and officers of AVC are expected to resign, other than Joanne Yan, who is expected to remain a director, and the following board of directors and management team are expected to be appointed:

Mr. Matheson, chief executive officer and director 

Mr. Matheson has spent over 35 years of his career in the investment and capital markets industries and is an experienced and seasoned senior executive in diverse areas of finance, capital markets, entrepreneurship and investing. Among his accomplishments are multiple financings in excess of $1-billion of both public and private companies in the biotechnology, technology, mining, oil and gas industries as well as numerous venture start-ups. Mr. Matheson began his career at Wood Gundy in 1983 becoming vice-president and director. He left Wood Gundy in 1995 to spearhead the Calgary operations of Canaccord Capital Corp. and after several years moved to Bolder Investment Partners, starting up its Calgary operations. In 2010, Bolder merged and Mr. Matheson and his colleagues moved to other independent investment firms concluding with Aligned Capital Partners Inc. until late 2019. A significant amount of Mr. Matheson’s career has been spent in capital markets advisory and risk management services to companies and industries that require his expertise. In late 2019, Mr. Matheson commenced the operation of Renaissance Mercantile Corp., a privately owned merchant bank where he is executive chairman and is a shareholder of Marvel Biotechnology Inc.

Mr. Matheson currently provides services as the president and chief executive officer of Marvel pursuant to an executive management and administrative services agreement from Renaissance Mercantile Corp.

Dr. Mark Williams, president, chief science officer and director 

Dr. Williams is chief scientific officer of Marvel and has 15 years of experience in drug and medical device development having repurposed three drugs from preclinical studies directly to positive phase 2 data, including manufacturing and toxicology. Dr. Williams is the author of more than 12 patents and an inventor of DM199 (a recombinant protein) in phase 2 trials for stroke and kidney disease. Dr. Williams is also involved in the financing and collaboration/partnership side of life science companies, having assisted to secure arrangements with drug foundations, pharma companies and various government agencies including Health Canada and U.S. FDA.

Dr. Williams has a master in business administration from the University of Manitoba and a PhD from the University of Alberta.

Preston Maddin, chief financial officer 

Mr. Maddin has been a chartered professional accountant for over 30 years and since 1983 has been president and chief executive officer of Pan-Meridian Capital Corp., a private management, investment and consulting company that provides independent executive contract services to junior and emerging private and public companies with an emphasis on companies in the biotechnology and medical device sector. Mr. Maddin has over 38 years of experience with domestic, international private and public company equity and debt financings, stock exchange listings and advisory to board and management teams, corporate capital structuring, corporate acquisitions of assets and or shares, executive contract management and corporate governance.

Mr. Maddin has a bachelor of commerce degree from the University of Saskatchewan.

Mr. Maddin provides services as the chief financial officer of Marvel pursuant to an executive management and administrative services agreement from Renaissance Mercantile Corp.

Ms. Yan, director

Ms. Yan has extensive public company experience having been a leading director, a governance committee chair and executive officer of numerous companies listed on the TSX-V and the Toronto Stock Exchange. Since September, 1994, Ms. Yan has been president of Joyco Consulting Services Inc., a wholly owned private Vancouver, B.C., company, providing business consulting services particularly with respect to mergers and acquisitions and related public and private financings.

Jacqueline Groot, corporate secretary

Ms. Groot began her career in the investment industry with Wood Gundy in 1987 and was a licensed investment adviser at Wood Gundy and Canaccord Capital Corp. until 1998. From 2010, Ms. Groot was a licensed investment adviser with the independent firms Sora Group Wealth Advisors, Jordan Capital Markets, Salman Partners and concluding with Aligned Capital Partners until late November, 2019. A significant amount of Ms. Groot’s career has been spent in capital markets advisory. She has extensive knowledge of capital markets, trade execution, financial products including derivatives, and investment themes. Ms. Groot also has a strong background in technical and relative strength market analysis. 

In late 2019, Ms. Groot joined the operation of Renaissance Mercantile Corp., a privately owned Calgary-based merchant bank where she is corporate secretary and director of administration. Ms. Groot currently provides services as corporate secretary of Marvel pursuant to an executive management and administrative services agreement from Renaissance Mercantile Corp.

The resulting issuer plans to expand the board of directors from three to five directors and to elect two additional nominees of Marvel as directors of the resulting issuer, conditional and effective on completion of the proposed transaction.

About Marvel

Marvel as described above, carries on the business as a biotechnology and life sciences company.

The attached table presents certain unaudited historical management-prepared financial information of Marvel for the financial year ended July 31, 2020, and is subject to further amendment and adjustment on completion of the year-end audit, inclusive of scientific research and experimental development disclosure or accruals as appropriate.

                                    Marvel (unaudited)
                                       as at July 31, 2020
Current assets                                    $259,810
Total assets                                      $260,147
Current liabilities                               $123,148
Total liabilities                                 $146,504
Shareholders' (or members') equity                $113,643
(deficit)

 

About Alphanco Venture Corp.

AVC is a capital pool company pursuant to the policies of the TSX Venture Exchange with a view to completing a qualifying transaction within 24 months of listing. Management of the company has been actively engaged in assessing possible projects with a view to completing an acquisition.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.